New combo may let esophageal cancer patients skip surgery
NCT ID NCT07603375
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving additional chemotherapy after the usual chemoradiation can better control esophageal cancer and reduce the need for surgery. About 60 adults with stage II to IVA esophageal adenocarcinoma will receive chemoradiation followed by more chemotherapy. The main goal is to see if the cancer disappears on biopsy after treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a swallowed balloon unlock the genetic secrets of esophageal cancer?
- Pulsing radiation may spare esophageal cancer patients from agonizing throat pain
- Personalized radiation pulses could boost esophageal cancer treatment
- Could a dye and camera spare esophageal cancer patients from extensive lymph node removal?
- Which biopsy method best spots early esophageal cancer?
- Can a simple blood test predict leukemia risk after cancer therapy?